• LAST PRICE
    25.4400
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    10.1800/ 2
  • Ask / Lots
    40.7000/ 2
  • Open / Previous Close
    --- / 25.4400
  • Day Range
    ---
  • 52 Week Range
    Low 9.1800
    High 53.7900
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 24.55
TimeVolumeQTTB
09:32 ET614025.005
09:35 ET151025.785
09:37 ET18625.405
09:39 ET102425.64
09:42 ET186825.535
09:44 ET10025.62
09:46 ET76325.23
09:48 ET25024.81
09:50 ET10025.225
09:51 ET10025.705
09:53 ET10025.705
09:55 ET10025.33
09:57 ET80024.63
10:04 ET23024.495
10:06 ET10024.97
10:08 ET10024.7
10:11 ET10024.7
10:13 ET10024.96
10:22 ET60024.995
10:24 ET100025.01
10:33 ET60225.16
10:36 ET40025.35
10:38 ET10024.92
10:44 ET110025.48
10:54 ET10026
10:56 ET50025.52
11:02 ET10025.55
11:03 ET10025.755
11:12 ET10025.55
11:16 ET10025.51
11:20 ET10025.635
11:21 ET382025.84
11:23 ET23525.99
11:32 ET46226
11:34 ET45625.85
11:38 ET146025.36
11:45 ET20025.345
11:48 ET100025.385
11:50 ET10025.385
11:59 ET10025.28
12:15 ET20025.25
12:17 ET127025.425
12:19 ET20025.43
12:24 ET20025.27
12:28 ET10025.43
12:30 ET10925.26
12:32 ET10025.4
12:33 ET30025.31
12:35 ET10025.41
12:37 ET90025.47
12:48 ET70025.415
12:50 ET22025.415
12:53 ET10025.44
01:00 ET30025.35
01:04 ET20025.45
01:06 ET30225.49
01:08 ET53525.42
01:09 ET50825.2
01:13 ET43025.07
01:15 ET10025.32
01:18 ET10025.27
01:20 ET30025.13
01:22 ET25225.215
01:27 ET369325.09
01:29 ET122825.12
01:31 ET10025.12
01:38 ET70025
01:42 ET20024.98
01:44 ET10024.95
01:47 ET10024.93
02:02 ET10025.175
02:03 ET28325
02:09 ET365025.26
02:12 ET56725.25
02:20 ET20025.18
02:21 ET20025.175
02:23 ET122025.25
02:25 ET20025.2
02:32 ET10025.22
02:34 ET40025.31
02:36 ET70025.31
02:38 ET271025.46
02:39 ET10025.57
02:41 ET60025.545
02:43 ET20025.47
02:48 ET10025.34
02:50 ET90025.44
02:56 ET142025.64
02:57 ET19625.64
03:06 ET97025.52
03:08 ET30025.565
03:10 ET56325.64
03:12 ET10025.55
03:17 ET216825.74
03:19 ET10025.655
03:21 ET30025.67
03:28 ET173225.74
03:30 ET10025.74
03:32 ET142025.64
03:33 ET20025.58
03:37 ET40025.38
03:42 ET10025.395
03:44 ET10025.385
03:46 ET21025.43
03:48 ET30025.46
03:51 ET262025.46
03:53 ET231425.42
03:55 ET70525.14
04:00 ET1481425.44
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesQTTB
Q32 Bio Inc
299.0M
-3.4x
---
United StatesNAUT
Nautilus Biotechnology Inc
301.4M
-4.3x
---
United StatesNGNE
Neurogene Inc
301.6M
-5.0x
---
United StatesCMPS
Compass Pathways PLC
301.7M
-2.1x
---
United StatesLXRX
Lexicon Pharmaceuticals Inc
312.1M
-1.1x
---
United StatesALDX
Aldeyra Therapeutics Inc
288.8M
-6.6x
---
As of 2024-11-26

Company Information

Q32 Bio Inc. is a clinical-stage biotechnology company. The Company is engaged in developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its lead programs, focused on the IL-7 / TSLP receptor pathways and complement system, address immune dysregulation to help patients take back control of their lives. Its program for adaptive immunity, bempikibart (ADX-914), is a fully human anti-IL-7Ra antibody that re-regulates adaptive immune function for the treatment of autoimmune diseases. It is being evaluated in two Phase II trials for the treatment of atopic dermatitis and alopecia areata. Its program for innate immunity, ADX-097, is based on a platform enabling tissue-targeted regulation of the complement system without long-term systemic blockade. The Company has completed a first-in-human, Phase I ascending dose clinical study of ADX-097 in healthy volunteers.

Contact Information

Headquarters
830 Winter StreetWALTHAM, MA, United States 02451
Phone
781-999-0232
Fax
302-655-5049

Executives

Independent Chairman of the Board
Mark Iwicki
President, Chief Financial Officer, Treasurer
Lee Kalowski
Chief Executive Officer, Company Secretary, Director
Jodie Morrison
Chief Scientific Officer and President of Research
Shelia Violette
Chief Medical Officer
Jason Campagna

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$299.0M
Revenue (TTM)
$0.00
Shares Outstanding
12.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.45
EPS
$-7.44
Book Value
$22.64
P/E Ratio
-3.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.